What question did this study set out to answer?

The research explores barriers to artificial intelligence adoption in CMC and supply chain operations.

December 11, 2025

Digitizing CMC: opportunities and constraints for artificial intelligence adoption across CGT development and manufacturing

Puntos clave

The research explores barriers to artificial intelligence adoption in CMC and supply chain operations.
Qualitative interviews
Expert discussions
Analysis of current development practices
Identified constraints related to digitization and regulatory considerations
Potential for AI to reduce development timelines
Opportunities for improved operational resilience through AI integration

Resumen

“...I expect AI to accelerate readiness for clinical and commercial operations by several years, alleviating longstanding bottlenecks across development and launch.”Ashling Cannon (Commissioning Editor, Cell & Gene Therapy Insights) speaks with Kumar Dhanasekharan (SVP, Head of Technical Operations, Voyager Therapeutics Inc.) about the digitization barriers limiting artificial intelligence adoption in CMC and supply chain operations for cell and gene therapies, and the technical and regulatory considerations required to achieve real-time orchestration and operational resilience.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Kumar Dhanasekharan (Thu,) studied this question.

synapsesocial.com/papers/69401b1e2d562116f28f77cf https://doi.org/https://doi.org/10.18609/cgti.2025.159

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar